OPRL1 and melanoma: Orthotopic B16F10-OVA melanoma cells (2×105) were inoculated into the right hind paws of wild-type mice, which subsequently received daily intradermal injections of vehicle (50 μL) or the OPRL1 antagonist SB612111 (3 mM; 50 μL), starting one day post-inoculation.